News

2017 News Releases

Webcast ImageWebcast
Aralez Pharmaceuticals Inc at RBC Capital Markets 2017 Healthcare Conference  (Replay)
02/22/17 at 1:35 p.m. ET
Aralez Pharmaceuticals Inc at RBC Capital Markets 2017 Healthcare Conference
Wednesday, February 22, 2017 1:35 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016
DateTitle 
02/16/17Aralez to Present at the RBC Capital Markets Global Healthcare Conference
MISSISSAUGA, Ontario, Feb. 16, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the RBC Capital Markets Global Healthcare Conference to be held February 22-23, 2017. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:35 p.m. local time on Wednesday, February 22, 2017. A live webcast and audio archive for the event may be accessed ... 
Printer Friendly Version
02/13/17Aralez To Ring Closing Bell At Nasdaq On February 14, 2017
MISSISSAUGA, Ontario, Feb. 13, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York at 4:00 p.m. ET on Tuesday, February 14, 2017 to celebrate its commitment to cardiovascular disease and the commercial launch of Yosprala®. Chief Executive Officer, Adrian Adams, will perform the honorary bell ringing ceremony that w... 
Printer Friendly Version
02/02/17Aralez Pharmaceuticals unveils new office in Ireland
... 
Printer Friendly Version
01/11/17Aralez Announces Issuance Of Additional U.S. Patent For Yosprala
MISSISSAUGA, Ontario, Jan. 11, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent entitled "Compositions and Methods for Delivery of Omeprazole Plus Acetylsalicylic Acid" that covers Yosprala™ (aspirin and omeprazole), the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and the proton pump inhibitor, omepra... 
Printer Friendly Version
01/09/17Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040
MISSISSAUGA, Ontario, Jan. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational candidate, PA10040, for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. "As we seek to maximize the opportunity for Yosprala on a worldwide basis, we plan to e... 
Printer Friendly Version
01/09/17Aralez Provides Update On PBM Formulary Status For Yosprala
-Secures Formulary Status with Express Scripts Inc. for Yosprala™- MISSISSAUGA, Ontario, Jan. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that it has entered into a rebate agreement with Express Scripts Inc., which secures formulary status for Yosprala™, the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and a proton pump inhibitor, omeprazole, in the United States. The rebate agreement... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.